Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Yokohama City University 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Department of Radiation Oncology, Graduate School of Medicine, Yokohama City University 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Medicina (Kaunas). 2018 Jul 30;54(4):52. doi: 10.3390/medicina54040052.
The aim of present study was to compare the treatment results of daily cisplatin (CDDP), weekly docetaxel (DOC) intra-arterial infusion chemotherapy combined with radiotherapy (DIACRT) regimen and weekly CDDP intra-arterial infusion chemotherapy combined with radiotherapy (WIACRT) for patients with tongue cancer. Between January 2007 and December 2016, a total of 11 patients treated with WIACRT and 45 patients treated with DIACRT were enrolled in the present study. In the DIACRT group, 25 patients had late T2, and 20 patients had T3. A total of nine patients had late T2 and two had T3 in WIACRT ( = NS). In DIACRT, the treatment schedule consisted of intra-arterial chemotherapy (DOC, total 60 mg/m²; CDDP, total 150 mg/m²) and daily concurrent radiotherapy (RT) (total, 60 Gy). In WIACRT, the treatment schedule consisted of intra-arterial chemotherapy (CDDP, total 360 mg/m²) and daily concurrent RT (total, 60 Gy). The median follow-up periods for DIACRT and WIACRT were 61 and 66 months, respectively. The five-year local control (LC) and overall survival (OS) rate were 94.5% and 89.6% for the DIACRT group, and 60.6% and 63.6% for the WIACRT group, respectively. The LC rate and OS of the DIACRT group were significantly higher than those of the WIACRT group. As regards toxicities, no treatment-related deaths were observed during the follow-up periods in both groups. DIACRT was found to be feasible and effective for patients with tongue cancer and could become a new treatment modality.
本研究旨在比较每日顺铂（CDDP）、每周多西紫杉醇（DOC）动脉内灌注化疗联合放疗（DIACRT）方案与每周 CDDP 动脉内灌注化疗联合放疗（WIACRT）治疗舌癌患者的治疗结果。2007 年 1 月至 2016 年 12 月，本研究共纳入 11 例接受 WIACRT 治疗和 45 例接受 DIACRT 治疗的患者。在 DIACRT 组中，25 例为晚期 T2，20 例为 T3。WIACRT 组中共有 9 例为晚期 T2，2 例为 T3（= NS）。在 DIACRT 中，治疗方案包括动脉内化疗（DOC，总量 60mg/m²；CDDP，总量 150mg/m²）和每日同步放疗（RT）（总量 60Gy）。在 WIACRT 中，治疗方案包括动脉内化疗（CDDP，总量 360mg/m²）和每日同步 RT（总量 60Gy）。DIACRT 和 WIACRT 的中位随访时间分别为 61 个月和 66 个月。DIACRT 组的 5 年局部控制（LC）和总生存率（OS）分别为 94.5%和 89.6%，WIACRT 组分别为 60.6%和 63.6%。LC 率和 OS 方面，DIACRT 组明显高于 WIACRT 组。关于毒性，两组在随访期间均未观察到与治疗相关的死亡。DIACRT 对舌癌患者是可行且有效的，可能成为一种新的治疗方法。
